Rewriting the biosimilar playbook
Biosimilars represent one of the most powerful opportunities to reduce specialty drug costs for payers and members and expand access to effective therapies—but adoption has lagged due to market, regulatory, and clinical barriers.
At Asembia 2026, Arpit Patel, MedImpact SVP Trade Relations & Supply Chain, led a session that explored the forces shaping biosimilar adoption, including provider and member hesitancy, contracting dynamics, and supply chain complexity. He also outlined strategies to accelerate adoption.
If you weren’t able to attend his presentation, read the recap in Specialty Pharmacy Continuum.
DRIVING MEMBER AFFORDABILITY
At MedImpact, we are intensely focused on improving affordability for members and our approach to biosimilars is one part of that strategy.
In an interview with Managed Healthcare Executive, Arpit shared additional insights into how biosimilars can help plans achieve upfront savings while reducing the burden of high drug costs for members. Read the article.
At MedImpact, we believe that pharmacies are critical to better patient care.
That's why our unbranded biosimilar strategy was designed to not only deliver low-cost medications– but also ensure that these therapies are available to any licensed specialty pharmacy in the nation.
Medication non-adherence is a significant challenge for all healthcare payers but, given its role in CMS Star Ratings, it bears particular weight f
In today’s complex healthcare landscape, controlling costs and improving member health outcomes is more important than ever.
Ready for a change?
